Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6666822 | 1.00 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7164479 | 0.88 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23766688 | 0.88 | CYP3A4 (0.43) | SLC7A5CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL17978113 | 0.87 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL630703 | 0.87 | SLC7A5 (0.57) | SLC7A5 | |
| SCHEMBL7464405 | 0.87 | SLC7A5 (0.57) | SLC7A5 | |
| SCHEMBL17978114 | 0.87 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL594571 | 0.87 | SLC7A5 (0.57) | SLC7A5 | |
| SCHEMBL16355708 | 0.86 | TP53 (0.45) | SLC7A5PTPN1GRB2DPP4DPP8 | |
| SCHEMBL7340685 | 0.86 | CTSS (0.47) | SLC7A5CYP3A4CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687297-B1 | TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC BIOSCIENCES INC (CA) | 2014-06-18 | — | — | EP | disclosed |
| US-7683061-B2 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2010-03-23 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7105701-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-17 | — | — | US | disclosed |
| US-20020055651-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-05-09 | — | — | US | disclosed |
| WO-2001042193-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1019075-A4 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1019075-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Advanced Medicine, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999064035-A9 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999064035-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055651-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | SLC7A5 4017/4885CYP3A4 1843/4885CYP1A2 659/4885 |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | SSB, TLR5, ICOS | SLC7A5 1479/4885CYP3A4 4067/4885CYP1A2 2257/4885 |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | SLC7A5 4084/4885CYP3A4 1710/4885CYP1A2 666/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | SLC7A5 4063/4885CYP3A4 1760/4885CYP1A2 601/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | SLC7A5 4063/4885CYP3A4 1760/4885CYP1A2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.